A promising treatment, retatrutide, is generating considerable excitement within the Australian weight loss community. Designed by Eli Lilly , this combination GIP and GLP-1 agonist appears to provide more impressive outcomes than current therapies. Initial scientific trials have shown exceptional decreases in physical fat , suggesting a for a diff